Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...
The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...
GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...
Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...
Professor Sarah Blagden, from the University of Oxford, will co-lead the new GSK-Oxford Cancer Immuno-Prevention Programme, which is backed by £50 million from GSK. She told BBC Radio 4’s Today ...
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore the potential of cancer prevention through vaccination. The partnership ...
GSK and Oxford researchers to create cancer vaccine to stop disease developing - GSK will invest up to £50 million in the new ...
GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback